Here's what we'll cover
Here's what we'll cover
Early coverage of GLP-1 medications was mostly about how well they work. The conversation has matured. Obesity specialists, regulators, and nutrition groups now spend as much time on how these drugs are prescribed, monitored, and stopped as on the drugs themselves.
That shift is not a reason to panic if you take Ozempic, Wegovy, Mounjaro, or Zepbound. It is a reason to make sure your care matches what the evidence recommends.
What Experts Are Actually Concerned About
The benefits are well established. In the STEP 1 trial, semaglutide 2.4 mg produced an average weight loss of about 15% over 68 weeks, and tirzepatide produced up to about 21% in SURMOUNT 1. The concerns are about using these drugs safely at scale:
- Loss of muscle along with fat when protein and strength training are neglected
- Nutritional gaps when appetite drops sharply
- Rapid weight regain when treatment stops without a plan
- Prescriptions issued with little screening or follow up
- Products sold outside the regulated drug supply
Muscle Loss Deserves Real Attention
Any significant weight loss includes some lean tissue. In trial body composition substudies, lean mass made up roughly a quarter to two fifths of the weight lost on GLP-1 medications. Muscle matters for strength, metabolism, balance, and long term weight maintenance, especially in older adults.
A 2025 joint advisory from four major obesity and nutrition organizations, summarized by The Obesity Society, lists adequate protein and strength training as core priorities for anyone on GLP-1 therapy. Many clinicians aim for about 1.2 to 1.6 grams of protein per kilogram of body weight per day during active weight loss, along with resistance exercise two or three times per week. Ask your provider what target fits you.
Side Effects Worth Knowing Beyond Nausea
Digestive Problems
Nausea, vomiting, diarrhea, and constipation are common, particularly during dose increases, and usually ease with time. Persistent vomiting, severe bloating, or feeling full after a few bites deserves a call to your provider. Vomiting and diarrhea can also cause dehydration, which the labels list as a risk for kidney injury.
Pancreas and Gallbladder
The Wegovy prescribing information warns about acute pancreatitis and gallbladder problems, including gallstones. Severe abdominal pain that spreads to the back, with or without vomiting, needs prompt medical care.
Eyes
In 2025 the European Medicines Agency concluded that NAION, a sudden loss of blood flow to the optic nerve, is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. Sudden painless vision loss in one eye needs same day evaluation.
Mood and Mental Health
Earlier reports raised questions about suicidal thoughts. In January 2026 the FDA asked manufacturers to remove the suicidal behavior and ideation warning from Wegovy, Zepbound, and Saxenda labels after reviewing 91 placebo controlled trials with more than 107,000 participants and a cohort of more than 2 million people, and finding no increased risk. Any meaningful change in mood should still be reported to your provider.
Nutritional Gaps: The Quiet Risk
Eating much less can mean eating a narrower range of foods. Fatigue, hair thinning, brittle nails, or numbness can signal a deficiency. Practical steps include:
- Build meals around protein first, then vegetables and whole grains
- Ask whether a daily multivitamin makes sense for you
- Request labs such as vitamin B12, iron studies, and vitamin D if symptoms appear
- Consider a registered dietitian experienced with GLP-1 patients
What Happens When You Stop
Weight regain after stopping is the rule, not the exception. In the STEP 1 extension, people regained about two thirds of their lost weight within a year of stopping semaglutide. In SURMOUNT 4, people switched from tirzepatide to placebo regained much of their weight while those who continued kept losing. Ask about a long term plan before you start:
- What is the plan if I want to stop or cannot afford the medication?
- Would a lower maintenance dose be an option?
- Which habits should I build now to protect my results?
- How long do you expect me to stay on treatment?
Who Should Be Most Cautious
| Patient profile | Key concern | Recommended action |
|---|---|---|
| Personal or family history of medullary thyroid cancer or MEN 2 | Boxed warning for thyroid C cell tumors | Do not use; discuss alternatives |
| History of pancreatitis | Labeled pancreatitis risk | Careful risk and benefit discussion |
| Older adults | Greater impact of muscle and bone loss | Prioritize protein and strength training |
| History of eating disorders | Appetite suppression may worsen disordered patterns | Coordinate with a mental health professional |
| Pregnant or planning pregnancy | Not approved in pregnancy | Stop before conception; Wegovy label advises at least two months |
| Diabetes on insulin or sulfonylureas | Risk of low blood sugar | Doses of other medicines may need adjusting |
The Prescribing and Sourcing Problem
Telehealth has made GLP-1 care easier to reach, and quality varies widely. A responsible provider should:
- Review your full medical history and current medications
- Order baseline labs such as HbA1c, kidney function, and lipids
- Screen for contraindications including thyroid cancer history and pancreatitis
- Give you a clear dose escalation plan and side effect instructions
- Schedule regular follow up and adjust treatment when needed
Sourcing matters just as much. Compounded GLP-1 drugs are not FDA approved, and the FDA has raised concerns about unapproved GLP-1 products, including research only products and different salt forms of semaglutide. In June 2026 the agency sent warning letters to 25 telehealth companies over misleading claims about compounded products, as reported by Bloomberg Law. Lower cost legitimate options now exist, including manufacturer self pay programs and GLP-1 coupons and savings programs.
No waiting list. No insurance needed.
Frequently Asked Questions
Are GLP-1 medications safe to take long term?
Semaglutide and tirzepatide have been studied for several years in large trials, including cardiovascular outcome trials, and are designed for long term use. Like any medication they carry risks, so ongoing monitoring of side effects, nutrition, and labs is important.
What are the most serious risks of GLP-1 medications?
Serious but uncommon risks include pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar when combined with insulin or sulfonylureas, and very rarely NAION. They are not used in people with a personal or family history of medullary thyroid cancer or MEN 2.
Can you lose too much muscle on a GLP-1?
Some lean mass loss happens with any significant weight loss. Adequate protein and regular strength training are the main ways to protect muscle. Many clinicians target about 1.2 to 1.6 grams of protein per kilogram of body weight per day.
Do GLP-1 medications cause suicidal thoughts?
In January 2026 the FDA asked manufacturers to remove the suicidal behavior warning from Wegovy, Zepbound, and Saxenda labels after a large review found no increased risk. Any significant mood change should still be reported to your provider.
What happens when you stop a GLP-1 medication?
Most people regain a substantial share of lost weight. In the STEP 1 extension, people regained about two thirds of their weight loss within a year of stopping semaglutide. Discuss a maintenance plan before stopping.
Is it safe to get GLP-1 medications through telehealth?
It can be, if the provider reviews your history, orders labs, screens for contraindications, and follows up regularly. Be cautious with compounded or research only products, which are not FDA approved.
The Bottom Line
Experts raising GLP-1 safety questions are not arguing against these medications. They are arguing for better care around them: enough protein and strength training to protect muscle, attention to nutrition, honest planning for what happens if treatment stops, and prescribers who screen, monitor, and adjust.
Some concerns have also eased. The FDA's 2026 review found no increased risk of suicidal thoughts with GLP-1 weight loss drugs. Others, like pancreatitis, gallbladder disease, and the rare eye condition NAION, are real but uncommon and worth knowing about.
Bring these questions to your next appointment: What labs should I get and how often? How are we protecting my muscle? What should I do if side effects get worse? What is our plan if I stop? If your current setup cannot answer them, compare vetted telehealth providers that offer ongoing clinical support. Always consult your physician before making changes to your treatment.